23348-99-4

Basic information

• Product Name: 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBOXYLIC ACID
• Synonyms: 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBOXYLIC ACID;1-(4-nitrophenyl)cyclopropane-1-carboxylic acid;1-(4-nitrophenyl)-1-cyclopropanecarboxylic acid
• CAS NO: 23348-99-4
• Molecular Formula: C₁₀H₉NO₄
• Molecular Weight: 207.18276
• Mol File: 23348-99-4.mol

Chemical Properties

• Melting Point: 190.5-193 °C
• Boiling Point: 403.8°C at 760 mmHg
• Flash Point: 179.6°C
• Appearance: /
• Density: 1.48g/cm³
• Vapor Pressure: 3.02E-07mmHg at 25°C
• Refractive Index: 1.646
• PKA: 3.78±0.20(Predicted)
• CAS DataBase Reference: 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBOXYLIC ACID(23348-99-4)
• EPA Substance Registry System: 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBOXYLIC ACID(23348-99-4)

Safety Data

• Hazardous Substances Data: 23348-99-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
1-(4-NITRO-PHENYL)-CYCLOPROPANECARBOXYLIC ACID is used as a chemical intermediate for the synthesis of pharmaceutical drugs. Its structure allows for potential applications in creating covalent bonds between certain types of molecules, which is crucial in drug design and development.
Used in Chemical Research:
In the field of chemical research, 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBOXYLIC ACID is used as a reagent in various chemical reactions. Its nitrophenyl component makes it a valuable compound for studying the properties and behavior of nitrophenyl compounds in different reaction conditions.
Used in Organic Chemistry:
1-(4-NITRO-PHENYL)-CYCLOPROPANECARBOXYLIC ACID is used as a building block in the synthesis of more complex organic molecules. Its cyclopropane carboxylic acid group and nitrophenyl group provide a unique combination of functional groups that can be exploited in the construction of novel organic compounds.
Note: Due to the lack of data on the physical properties, safety, handling, and storage considerations of 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBOXYLIC ACID, it is essential to exercise caution when working with 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBOXYLIC ACID and to follow appropriate safety protocols.

InChI:InChI=1/C10H9NO4/c12-9(13)10(5-6-10)7-1-3-8(4-2-7)11(14)15/h1-4H,5-6H2,(H,12,13)

Upstream product

• 6120-95-2 1-phenyl-1-cyclopropane carboxylic acid 
• 555-21-5 4-Nitrophenylacetonitrile 
• 5445-26-1 ETHYL 4-NITROPHENYLACETATE 
• 408328-42-7 1-(4-nitrophenyl)-1-cyclopropylcarbonitrile 
• 1308814-98-3 ethyl 1-(4-nitrophenyl)cyclopropanecarboxylate 

Downstream Products

• 23349-00-0 1-(4-nitrophenyl)-hydroxymethylcyclopropane 
• 23348-98-3 methyl 1-(4-nitrophenyl)cyclopropanecarboxylate 
• 6921-44-4 4-nitrophenylcyclopropane 
• 1105636-57-4 tert-butyl (1-(4-nitrophenyl)cyclopropyl)carbamate 
• 1308815-49-7 tert-butyl ((1-(4-aminophenyl)cyclopropyl)methyl)(cyclopropyl)carbamate 
• 1308815-47-5 tert-butyl cyclopropyl((1-(4-nitrophenyl)cyclopropyl)methyl)carbamate 
• 1308815-46-4 N-((1-(4-nitrophenyl)cyclopropyl)methyl)cyclopropanamine 
• 1308815-45-3 (1-(4-nitrophenyl)cyclopropyl)methylmethanesulfonate 
• 1308815-51-1 tert-butyl ((1-(4-(((benzyloxy)carbonyl)amino)phenyl)cyclopropyl)methyl)(cyclopropyl)carbamate 
• 1308814-98-3 ethyl 1-(4-nitrophenyl)cyclopropanecarboxylate 

Relevant articles and documents

Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation

Abstract: LSD1 is a lysine demethylase highly involved in initiation and development of cancer. To design highly effective covalent inhibitors, a strategy is to fill its large catalytic cleft by designing tranylcypromine (TCP) analogs decorated with long,

Preparation method of cycloalkane compound

The invention provides a preparation method of a cycloalkane compound, and concretely provides a new cycloalkane construction method for preparing a compound represented by formula I. The preparationmethod is green and environment-friendly.

Electrophilic Bromolactonization of Cyclopropyl Diesters Using Lewis Basic Chalcogenide Catalysts

An efficient and regioselective electrophilic bromolactonization of cyclopropylmethyl diesters using triphenylphosphine sulfide (Ph3PS) or diphenyl selenide (Ph2Se) as the Lewis basic chalcogenide catalyst has been developed. It was observed that Ph3PS favored the formation of anti-diastereomer and yielded the multi-functional γ-lactones. Interestingly, the diastereoselectivity was reversed when using Ph2Se as a catalyst where the syn-product instead of the anti-product was favored. (Figure presented.).

HETEROCYCLIC COMPOUND

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

IMIDAZO COMPOUNDS AND USES THEREOF

N-substituted imidazopyrazinone compounds such as N-alkylated/aralkylated 7H-imidazo[1,2-a]pyrazin-8-one compounds and related analogs are disclosed. Pharmaceutical compositions and kits containing the N-substituted imidazopyrazinone compounds, as well as therapeutic uses thereof, including treatment of arrhythmia, are also disclosed.

Substituted alkanoic acids

The invention is directed to physiologically active compounds of general formula (I): wherein:- represents (i) a saturated 3 to 6 membered carbocycle, optionally substituted by one or more alkyl groups, (ii) indanyl or (iii) a saturated 4 to 6 membered heterocyclic ring; R1 represents R3Z1-Het- or R4N(R5)—C(═O)—NH—Ar1—; L1 represents an —R6—R7— linkage; R2 represents hydrogen, halogen, lower alkyl or lower alkoxy; L2 represents an alkylene linkage; Y is carboxy or an acid bioisostere; and their corresponding N-oxides or prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their corresponding N-oxides or prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4β1).

1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS

The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Thermal Decomposition of

A series of tert-butyl 1-arylcycloalkyl peresters was prepared, and the rate constants for the peresters' thermal decomposition were measured at several temperatures. The decomposition rates and aryl-substituent effects on the decomposition rates for the three series of peresters are remarkably similar to each other and to the acyclic α,α-dimethylbenzyl analogue previously investigated. The magnitude of the activation parameters for the rates of thermolysis of the alicyclic peresters and the solvent viscosity effects on these rates suggest that the 1-arylcyclobutyl (2), -cyclopentyl (3), and -cyclohexyl (4) peresters undergo thermal decomposition primarily by the concerted, two-bond-cleavage mechanism and that the 1-arylcyclopropyl peresters (1) undergo thermolysis primarily by the stepwise mechanism.